The Scientist

» pharma

Most Recent

image: Legionnaires’ Bacteria at GSK

Legionnaires’ Bacteria at GSK

By | August 14, 2015

GlaxoSmithKline temporarily shuts down a manufacturing plant in North Carolina after Legionella bacteria are detected in two external cooling towers.

0 Comments

image: Teva Buys Allergan Generics for $40.5 Billion

Teva Buys Allergan Generics for $40.5 Billion

By | July 27, 2015

Meanwhile, Allergan acquires drug developer Naurex in a $560 million deal. 

0 Comments

image: Biotech Buys Autoimmune Firm for $7B

Biotech Buys Autoimmune Firm for $7B

By | July 16, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: Endo to Pay $8 Billion for Par

Endo to Pay $8 Billion for Par

By | May 19, 2015

The deal would create one of the five biggest generic drugmakers in the U.S.

0 Comments

image: 23andMe Enters Drug Development

23andMe Enters Drug Development

By | March 12, 2015

The personal genomics firm announces plans to make medicines.

4 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Roche Buys Biotech for $8.3B

Roche Buys Biotech for $8.3B

By | August 27, 2014

The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.

0 Comments

image: Roche Set to Buy RNAi Firm

Roche Set to Buy RNAi Firm

By | August 6, 2014

The Swiss pharmaceutical giant will reportedly pay $450 million for a Danish biotech company that develops drugs that silence microRNAs.

2 Comments

image: EMA Gearing Up for Transparency

EMA Gearing Up for Transparency

By | June 16, 2014

The European Medicines Agency is preparing for a new policy that will release rarely-seen clinical trial reports for independent scrutiny.  

0 Comments

image: Merck Snaps Up Biotech for $3.85B

Merck Snaps Up Biotech for $3.85B

By | June 10, 2014

The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.

0 Comments

Popular Now

  1. Unstructured Proteins Help Tardigrades Survive Desiccation
  2. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  3. Opinion: On “The Impact Factor Fallacy”
  4. Inflammation Drives Gut Bacteria Evolution
Business Birmingham